Cytoki Pharma Reports Results from the P-I Study of CK-0045 to Improve Cardiometabolic Risk Factors
Shots:
- Cytoki Pharma reported results from the P-Itrial assessing the safety, tolerability & PK of CK-0045 (IL-22 analog) among healthy & otherwise healthy obese subjects
- The study verified CK-0045’s target engagement by liver & gut biomarkers with PK data supporting QW SC dosing and showed reductions in body mass, LDL cholesterol, blood insulin & insulin resistance, specifically in those with decreased insulin sensitivity; the drug was safe & well-tolerated
- The above results will form the basis of P-II PoC trials investigating CK-0045 among obese & T2D participants for further evaluation, expected to be conducted during H2’24
Ref: PR Newswire | Image: Novo Nordisk
Related News:- Neomorph and Novo Nordisk Partner to Discover Molecular Glue Degraders for Cardiometabolic and Rare Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
